Bionano Genomics Stock Forecast, Price & News

-0.10 (-1.68 %)
(As of 07/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume7.31 million shs
Average Volume11.58 million shs
Market Capitalization$1.64 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BNGO News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionano Genomics and its competitors with MarketBeat's FREE daily newsletter.

Bionano Genomics logo

About Bionano Genomics

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.18 out of 5 stars

Medical Sector

2047th out of 4,434 stocks

Analytical Instruments Industry

45th out of 72 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Bionano Genomics (NASDAQ:BNGO) Frequently Asked Questions

Is Bionano Genomics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionano Genomics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bionano Genomics stock.
View analyst ratings for Bionano Genomics
or view top-rated stocks.

What stocks does MarketBeat like better than Bionano Genomics?

Wall Street analysts have given Bionano Genomics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bionano Genomics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bionano Genomics?

Bionano Genomics saw a decline in short interest in July. As of July 15th, there was short interest totaling 44,920,000 shares, a decline of 13.8% from the June 30th total of 52,100,000 shares. Based on an average trading volume of 20,770,000 shares, the short-interest ratio is currently 2.2 days. Approximately 16.2% of the shares of the company are sold short.
View Bionano Genomics' Short Interest

When is Bionano Genomics' next earnings date?

Bionano Genomics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Bionano Genomics

How were Bionano Genomics' earnings last quarter?

Bionano Genomics, Inc. (NASDAQ:BNGO) issued its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The firm had revenue of $3.17 million for the quarter, compared to analyst estimates of $2.80 million. Bionano Genomics had a negative net margin of 384.80% and a negative trailing twelve-month return on equity of 40.47%.
View Bionano Genomics' earnings history

How has Bionano Genomics' stock been impacted by Coronavirus (COVID-19)?

Bionano Genomics' stock was trading at $0.5770 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BNGO shares have increased by 917.3% and is now trading at $5.87.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BNGO?

5 brokerages have issued 12-month price targets for Bionano Genomics' shares. Their forecasts range from $1.25 to $15.00. On average, they expect Bionano Genomics' share price to reach $10.06 in the next year. This suggests a possible upside of 71.4% from the stock's current price.
View analysts' price targets for Bionano Genomics
or view top-rated stocks among Wall Street analysts.

Who are Bionano Genomics' key executives?

Bionano Genomics' management team includes the following people:
  • Dr. Robert Erik Holmlin, Pres, CEO, Sec. & Director (Age 53, Pay $519.07k)
  • Mr. Christopher P. Stewart, Chief Financial Officer (Age 51, Pay $77.93k)
  • Mr. Mark Oldakowski, Chief Operating Officer (Age 47, Pay $376.1k)
  • Dr. Alka Chaubey FACMG, Ph.D., Chief Medical Officer (Age 48)
  • Mr. Robert J. Priar, Chief Commercial Officer
  • Mark Adamchak, Controller
  • Dr. Paul R. Selvin Ph.D., Scientific Advisor
  • Prof. Pui-Yan Kwok, Scientific Advisor
  • Dr. Charles Lee Ph.D., Scientific Advisor

What is R. Erik Holmlin's approval rating as Bionano Genomics' CEO?

10 employees have rated Bionano Genomics CEO R. Erik Holmlin on R. Erik Holmlin has an approval rating of 73% among Bionano Genomics' employees.

Who are some of Bionano Genomics' key competitors?

What other stocks do shareholders of Bionano Genomics own?

When did Bionano Genomics IPO?

(BNGO) raised $16 million in an initial public offering on the week of August 20th 2018. The company issued 2,500,000 shares at $6.00-$7.00 per share. Roth Capital Partners and Maxim Group acted as the underwriters for the IPO and LifeSci Capital was co-manager.

What is Bionano Genomics' stock symbol?

Bionano Genomics trades on the NASDAQ under the ticker symbol "BNGO."

Who are Bionano Genomics' major shareholders?

Bionano Genomics' stock is owned by a number of institutional and retail investors. Top institutional investors include XR Securities LLC (0.00%).
View institutional ownership trends for Bionano Genomics

Which major investors are selling Bionano Genomics stock?

BNGO stock was sold by a variety of institutional investors in the last quarter, including XR Securities LLC.
View insider buying and selling activity for Bionano Genomics
or view top insider-selling stocks.

How do I buy shares of Bionano Genomics?

Shares of BNGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bionano Genomics' stock price today?

One share of BNGO stock can currently be purchased for approximately $5.87.

How much money does Bionano Genomics make?

Bionano Genomics has a market capitalization of $1.64 billion and generates $8.50 million in revenue each year. The company earns $-41,110,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Bionano Genomics have?

Bionano Genomics employs 147 workers across the globe.

What is Bionano Genomics' official website?

The official website for Bionano Genomics is

Where are Bionano Genomics' headquarters?

Bionano Genomics is headquartered at 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121.

How can I contact Bionano Genomics?

Bionano Genomics' mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The company can be reached via phone at 858-888-7600 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.